FSD Pharma files base shelf prospectus

FSD Pharma is pleased to announce that in order to replace its prior base shelf prospectus that expired, it has filed and obtained a receipt for its preliminary short form base shelf prospectus dated November 3, 2023 to provide the company with the flexibility to take advantage of financing opportunities and favorable market conditions, if and when needed, during the 25-month period that the Prospectus, once made final, remains effective. However, there is no certainty any Securities will be offered or sold under the final Prospectus within the 25-month period. The Prospectus has been filed in each of the provinces and territories in Canada. The Prospectus, when final and effective, will enable the company to offer, issue and sell, from time to time: Class B subordinate voting shares, subscription receipts, warrants and units, or any combination thereof for up to an aggregate offering price of $50M, in one or more transactions during the Effective Period. Should the company decide to offer Securities during this period, the specific terms, including the use of proceeds from any offering of Securities, will be set forth in one or more related prospectus supplements to the final Prospectus.